| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paranasal Sinus Neoplasms | 22 | 2021 | 285 | 3.420 |
Why?
|
| Head and Neck Neoplasms | 33 | 2021 | 4148 | 3.370 |
Why?
|
| Salivary Gland Neoplasms | 12 | 2020 | 497 | 3.000 |
Why?
|
| Nose Neoplasms | 14 | 2021 | 243 | 2.000 |
Why?
|
| Carcinoma, Squamous Cell | 25 | 2019 | 5595 | 1.760 |
Why?
|
| Skull Base Neoplasms | 13 | 2023 | 339 | 1.640 |
Why?
|
| Carcinoma, Adenoid Cystic | 10 | 2023 | 444 | 1.330 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 9 | 2021 | 124 | 1.250 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2015 | 1464 | 1.110 |
Why?
|
| Carcinoma | 12 | 2023 | 2610 | 1.110 |
Why?
|
| Receptor, trkB | 3 | 2012 | 52 | 1.100 |
Why?
|
| Melanoma | 12 | 2018 | 5597 | 1.050 |
Why?
|
| Paraganglioma | 5 | 2018 | 200 | 1.040 |
Why?
|
| Carcinoma, Mucoepidermoid | 3 | 2011 | 141 | 1.020 |
Why?
|
| Nasal Cavity | 8 | 2021 | 155 | 0.990 |
Why?
|
| Endoscopy | 10 | 2023 | 495 | 0.970 |
Why?
|
| Maxillary Sinus Neoplasms | 5 | 2020 | 114 | 0.970 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2019 | 10402 | 0.860 |
Why?
|
| Skin Neoplasms | 8 | 2015 | 4899 | 0.790 |
Why?
|
| Laryngectomy | 3 | 2012 | 244 | 0.790 |
Why?
|
| Nasopharyngeal Neoplasms | 5 | 2022 | 340 | 0.780 |
Why?
|
| Neck Dissection | 6 | 2017 | 294 | 0.750 |
Why?
|
| Skull Base | 7 | 2023 | 224 | 0.750 |
Why?
|
| Retrospective Studies | 58 | 2023 | 39922 | 0.720 |
Why?
|
| Thyroid Neoplasms | 6 | 2018 | 1894 | 0.700 |
Why?
|
| Cisplatin | 4 | 2017 | 2499 | 0.690 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2014 | 508 | 0.680 |
Why?
|
| Vocal Cord Paralysis | 2 | 2012 | 95 | 0.670 |
Why?
|
| Male | 89 | 2023 | 128395 | 0.650 |
Why?
|
| Robotics | 4 | 2014 | 365 | 0.650 |
Why?
|
| Prosthesis Implantation | 2 | 2012 | 243 | 0.630 |
Why?
|
| Middle Aged | 70 | 2020 | 90450 | 0.620 |
Why?
|
| Disease-Free Survival | 22 | 2019 | 10267 | 0.610 |
Why?
|
| Combined Modality Therapy | 21 | 2022 | 9041 | 0.600 |
Why?
|
| Sarcoma | 5 | 2022 | 1851 | 0.590 |
Why?
|
| Humans | 121 | 2024 | 270601 | 0.590 |
Why?
|
| Paranasal Sinuses | 3 | 2020 | 64 | 0.590 |
Why?
|
| Robotic Surgical Procedures | 4 | 2020 | 536 | 0.560 |
Why?
|
| Maxillary Neoplasms | 1 | 2016 | 23 | 0.550 |
Why?
|
| Lymphatic Metastasis | 14 | 2017 | 4969 | 0.550 |
Why?
|
| Female | 81 | 2020 | 148790 | 0.540 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2008 | 69 | 0.530 |
Why?
|
| Aged | 54 | 2020 | 73534 | 0.530 |
Why?
|
| Carcinoma, Neuroendocrine | 4 | 2020 | 742 | 0.520 |
Why?
|
| Adult | 57 | 2022 | 81960 | 0.510 |
Why?
|
| Radiotherapy, Adjuvant | 10 | 2020 | 2272 | 0.500 |
Why?
|
| Research Support as Topic | 2 | 2020 | 122 | 0.500 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2016 | 166 | 0.500 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2015 | 290 | 0.490 |
Why?
|
| Fluorescein Angiography | 1 | 2015 | 151 | 0.480 |
Why?
|
| Laryngoplasty | 2 | 2012 | 29 | 0.480 |
Why?
|
| Adenocarcinoma | 8 | 2015 | 7919 | 0.470 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 116 | 0.470 |
Why?
|
| Laryngeal Diseases | 2 | 2012 | 55 | 0.460 |
Why?
|
| Carcinoma, Papillary | 2 | 2011 | 566 | 0.460 |
Why?
|
| Prognosis | 25 | 2021 | 22520 | 0.460 |
Why?
|
| Mouth Neoplasms | 4 | 2008 | 735 | 0.460 |
Why?
|
| Quinazolines | 2 | 2016 | 956 | 0.450 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2012 | 168 | 0.440 |
Why?
|
| Follow-Up Studies | 17 | 2018 | 15270 | 0.440 |
Why?
|
| Treatment Outcome | 31 | 2023 | 33811 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 5776 | 0.430 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 87 | 0.430 |
Why?
|
| Adolescent | 27 | 2020 | 32684 | 0.420 |
Why?
|
| Lymph Nodes | 2 | 2013 | 3081 | 0.420 |
Why?
|
| Neoplasm Staging | 18 | 2021 | 14021 | 0.410 |
Why?
|
| Succinate Dehydrogenase | 2 | 2011 | 48 | 0.410 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2012 | 20 | 0.400 |
Why?
|
| Salivary Glands, Minor | 1 | 2012 | 36 | 0.400 |
Why?
|
| Carotid Body Tumor | 1 | 2011 | 19 | 0.390 |
Why?
|
| Survival Rate | 16 | 2021 | 12527 | 0.390 |
Why?
|
| Punctures | 1 | 2012 | 102 | 0.380 |
Why?
|
| Hemangiopericytoma | 1 | 2011 | 59 | 0.380 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2011 | 131 | 0.380 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 84 | 0.370 |
Why?
|
| Risk Assessment | 7 | 2018 | 6762 | 0.370 |
Why?
|
| Oral Surgical Procedures | 1 | 2011 | 32 | 0.370 |
Why?
|
| Forecasting | 1 | 2013 | 699 | 0.370 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 4053 | 0.350 |
Why?
|
| Neoplasms, Experimental | 2 | 2006 | 784 | 0.350 |
Why?
|
| Aged, 80 and over | 25 | 2020 | 31084 | 0.350 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2011 | 142 | 0.350 |
Why?
|
| Neoplasm Metastasis | 8 | 2013 | 5318 | 0.350 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 14638 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2012 | 2454 | 0.340 |
Why?
|
| Laryngeal Neoplasms | 2 | 2012 | 530 | 0.340 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2020 | 1162 | 0.330 |
Why?
|
| Surgical Flaps | 1 | 2015 | 891 | 0.330 |
Why?
|
| Immunohistochemistry | 10 | 2014 | 7643 | 0.320 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2010 | 103 | 0.320 |
Why?
|
| Survival Analysis | 15 | 2018 | 9281 | 0.320 |
Why?
|
| Larynx | 1 | 2010 | 147 | 0.310 |
Why?
|
| Tyrphostins | 1 | 2009 | 110 | 0.310 |
Why?
|
| Biomedical Research | 2 | 2020 | 799 | 0.310 |
Why?
|
| Chordoma | 2 | 2022 | 170 | 0.310 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 2658 | 0.310 |
Why?
|
| Clinical Protocols | 1 | 2010 | 477 | 0.300 |
Why?
|
| Young Adult | 16 | 2020 | 22219 | 0.300 |
Why?
|
| Parotid Neoplasms | 3 | 2015 | 150 | 0.300 |
Why?
|
| Radiation Injuries | 3 | 2017 | 1476 | 0.300 |
Why?
|
| Child | 17 | 2021 | 30558 | 0.300 |
Why?
|
| Mesoderm | 1 | 2010 | 391 | 0.300 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 425 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 2 | 2024 | 593 | 0.290 |
Why?
|
| Pituitary Neoplasms | 1 | 2009 | 216 | 0.280 |
Why?
|
| Collagen | 1 | 2010 | 723 | 0.280 |
Why?
|
| Radiation Oncology | 2 | 2024 | 558 | 0.280 |
Why?
|
| Cell Line, Tumor | 11 | 2016 | 14876 | 0.280 |
Why?
|
| Program Evaluation | 1 | 2009 | 602 | 0.280 |
Why?
|
| Induction Chemotherapy | 3 | 2021 | 670 | 0.280 |
Why?
|
| Rare Diseases | 3 | 2016 | 360 | 0.270 |
Why?
|
| Anoikis | 1 | 2006 | 63 | 0.270 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 473 | 0.260 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 494 | 0.260 |
Why?
|
| STAT3 Transcription Factor | 2 | 2010 | 1132 | 0.260 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 316 | 0.250 |
Why?
|
| Biopsy, Needle | 4 | 2013 | 1381 | 0.250 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 3656 | 0.240 |
Why?
|
| Endolymphatic Sac | 1 | 2004 | 11 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1300 | 0.240 |
Why?
|
| Cell Proliferation | 5 | 2012 | 7232 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2020 | 4006 | 0.230 |
Why?
|
| Head | 2 | 2023 | 248 | 0.230 |
Why?
|
| Thyroidectomy | 2 | 2008 | 489 | 0.230 |
Why?
|
| Ear Neoplasms | 1 | 2004 | 64 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3416 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1901 | 0.210 |
Why?
|
| Epithelial Cells | 1 | 2010 | 1875 | 0.210 |
Why?
|
| Tracheostomy | 2 | 2023 | 253 | 0.200 |
Why?
|
| Ethmoid Sinus | 2 | 2014 | 27 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6257 | 0.200 |
Why?
|
| Lymph Node Excision | 3 | 2011 | 2068 | 0.200 |
Why?
|
| Child, Preschool | 7 | 2020 | 17075 | 0.190 |
Why?
|
| Pyridines | 1 | 2009 | 1313 | 0.190 |
Why?
|
| Mice, Nude | 5 | 2016 | 4332 | 0.190 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 4838 | 0.190 |
Why?
|
| Pheochromocytoma | 2 | 2018 | 310 | 0.190 |
Why?
|
| Foundations | 1 | 2020 | 21 | 0.190 |
Why?
|
| Voice Quality | 2 | 2012 | 35 | 0.180 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 682 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2007 | 1005 | 0.180 |
Why?
|
| Health Physics | 1 | 2020 | 62 | 0.180 |
Why?
|
| Injections | 2 | 2012 | 284 | 0.180 |
Why?
|
| Blotting, Western | 3 | 2012 | 3568 | 0.180 |
Why?
|
| Mycoses | 2 | 2015 | 393 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2020 | 9460 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 5417 | 0.170 |
Why?
|
| Vocal Cords | 2 | 2012 | 106 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2011 | 2124 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1825 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2020 | 7787 | 0.170 |
Why?
|
| Papilloma, Inverted | 1 | 2019 | 9 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 350 | 0.160 |
Why?
|
| Mice | 12 | 2016 | 35412 | 0.160 |
Why?
|
| Nasal Surgical Procedures | 1 | 2019 | 10 | 0.160 |
Why?
|
| Germ-Line Mutation | 2 | 2016 | 1101 | 0.160 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 1958 | 0.160 |
Why?
|
| Otolaryngology | 1 | 2020 | 146 | 0.160 |
Why?
|
| Medical Oncology | 2 | 2023 | 1464 | 0.160 |
Why?
|
| Gene Expression | 1 | 2006 | 3606 | 0.150 |
Why?
|
| Cadaver | 2 | 2009 | 202 | 0.150 |
Why?
|
| Neurosurgical Procedures | 3 | 2018 | 633 | 0.150 |
Why?
|
| Salivary Glands | 2 | 2020 | 139 | 0.150 |
Why?
|
| Incidence | 6 | 2023 | 5825 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 211 | 0.150 |
Why?
|
| Dura Mater | 1 | 2017 | 85 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 1503 | 0.140 |
Why?
|
| Nasal Mucosa | 1 | 2017 | 82 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2017 | 485 | 0.140 |
Why?
|
| Face | 1 | 2019 | 252 | 0.140 |
Why?
|
| Skull | 1 | 2019 | 251 | 0.140 |
Why?
|
| Gastrostomy | 1 | 2018 | 197 | 0.140 |
Why?
|
| Neck | 3 | 2015 | 394 | 0.140 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2018 | 100 | 0.140 |
Why?
|
| Chemoradiotherapy | 4 | 2019 | 2028 | 0.140 |
Why?
|
| Olfactory Bulb | 1 | 2017 | 120 | 0.140 |
Why?
|
| Fibula | 1 | 2017 | 153 | 0.130 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2014 | 57 | 0.130 |
Why?
|
| Thigh | 1 | 2017 | 165 | 0.130 |
Why?
|
| Chondrosarcoma | 1 | 2018 | 213 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2013 | 1127 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 223 | 0.130 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 341 | 0.130 |
Why?
|
| Physician's Role | 1 | 2018 | 228 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 517 | 0.130 |
Why?
|
| Extremities | 1 | 2017 | 311 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 879 | 0.130 |
Why?
|
| Animals | 13 | 2016 | 61346 | 0.130 |
Why?
|
| Lymphoscintigraphy | 1 | 2015 | 35 | 0.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2015 | 2178 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 930 | 0.120 |
Why?
|
| Intraoperative Period | 1 | 2015 | 251 | 0.120 |
Why?
|
| Radiotherapy Dosage | 4 | 2015 | 4020 | 0.120 |
Why?
|
| Proton Therapy | 2 | 2016 | 1637 | 0.120 |
Why?
|
| Myoepithelioma | 1 | 2015 | 30 | 0.120 |
Why?
|
| Equipment Design | 2 | 2009 | 1207 | 0.120 |
Why?
|
| Selection Bias | 1 | 2015 | 47 | 0.120 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2015 | 37 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 339 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2018 | 527 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 286 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2011 | 2360 | 0.120 |
Why?
|
| Indocyanine Green | 1 | 2015 | 125 | 0.120 |
Why?
|
| Re-Irradiation | 1 | 2016 | 166 | 0.120 |
Why?
|
| Registries | 4 | 2020 | 2209 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 144 | 0.120 |
Why?
|
| Weight Loss | 1 | 2018 | 628 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 16719 | 0.110 |
Why?
|
| Postoperative Complications | 5 | 2018 | 5673 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2017 | 2922 | 0.110 |
Why?
|
| Sinusitis | 1 | 2015 | 148 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 1270 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2011 | 9047 | 0.110 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2014 | 109 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 3205 | 0.110 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 907 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2013 | 168 | 0.110 |
Why?
|
| Risk Factors | 6 | 2019 | 17855 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 3582 | 0.110 |
Why?
|
| Craniotomy | 2 | 2018 | 303 | 0.110 |
Why?
|
| Orbital Neoplasms | 1 | 2015 | 234 | 0.110 |
Why?
|
| Disease Progression | 5 | 2023 | 6867 | 0.110 |
Why?
|
| Pericytes | 1 | 2013 | 90 | 0.110 |
Why?
|
| Mitosporic Fungi | 1 | 2012 | 19 | 0.110 |
Why?
|
| Deglutition | 1 | 2014 | 187 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 326 | 0.100 |
Why?
|
| Orbit | 1 | 2014 | 209 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 623 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 497 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 701 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2017 | 823 | 0.100 |
Why?
|
| Microvessels | 1 | 2013 | 145 | 0.100 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2012 | 71 | 0.100 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 144 | 0.100 |
Why?
|
| Texas | 4 | 2019 | 6445 | 0.100 |
Why?
|
| Mastocytoma, Skin | 1 | 2011 | 2 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 727 | 0.100 |
Why?
|
| Brain Abscess | 1 | 2012 | 74 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 1076 | 0.100 |
Why?
|
| Scalp Dermatoses | 1 | 2011 | 7 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5144 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 841 | 0.100 |
Why?
|
| Rheumatoid Nodule | 1 | 2011 | 6 | 0.100 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2012 | 123 | 0.100 |
Why?
|
| Hyoid Bone | 1 | 2011 | 8 | 0.100 |
Why?
|
| Larynx, Artificial | 1 | 2012 | 44 | 0.100 |
Why?
|
| Kisspeptins | 1 | 2011 | 12 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 6193 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2020 | 2413 | 0.090 |
Why?
|
| Biopsy | 2 | 2017 | 3491 | 0.090 |
Why?
|
| Tonsillar Neoplasms | 1 | 2011 | 81 | 0.090 |
Why?
|
| Lasers, Gas | 1 | 2011 | 14 | 0.090 |
Why?
|
| Suppression, Genetic | 1 | 2011 | 70 | 0.090 |
Why?
|
| Phenotype | 4 | 2012 | 6501 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 7912 | 0.090 |
Why?
|
| Epistaxis | 1 | 2010 | 32 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1608 | 0.090 |
Why?
|
| Nasal Obstruction | 1 | 2010 | 22 | 0.090 |
Why?
|
| Methylene Blue | 1 | 2011 | 53 | 0.090 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2022 | 50 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 685 | 0.090 |
Why?
|
| Coloring Agents | 1 | 2011 | 232 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2013 | 743 | 0.090 |
Why?
|
| Down-Regulation | 3 | 2013 | 2087 | 0.090 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 254 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2394 | 0.090 |
Why?
|
| Fiber Optic Technology | 1 | 2011 | 147 | 0.090 |
Why?
|
| Transcriptome | 1 | 2019 | 1958 | 0.090 |
Why?
|
| Quality of Life | 3 | 2022 | 4798 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 614 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 5923 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 284 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2013 | 12041 | 0.090 |
Why?
|
| Sella Turcica | 1 | 2009 | 23 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 1336 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 3924 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2011 | 364 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2020 | 13413 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2015 | 2258 | 0.080 |
Why?
|
| Chemotaxis | 1 | 2010 | 135 | 0.080 |
Why?
|
| Calibration | 1 | 2010 | 346 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 12038 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 982 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2018 | 1692 | 0.080 |
Why?
|
| Pyrroles | 1 | 2013 | 588 | 0.080 |
Why?
|
| SEER Program | 1 | 2013 | 1052 | 0.080 |
Why?
|
| Biotransformation | 1 | 2009 | 98 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 622 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2009 | 137 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2013 | 606 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 5238 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 201 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 4966 | 0.080 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 234 | 0.080 |
Why?
|
| Cell Survival | 2 | 2013 | 3058 | 0.080 |
Why?
|
| Endoscopes | 1 | 2007 | 41 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2010 | 487 | 0.070 |
Why?
|
| Indoles | 1 | 2013 | 1029 | 0.070 |
Why?
|
| Margins of Excision | 2 | 2020 | 315 | 0.070 |
Why?
|
| Age Factors | 2 | 2015 | 5441 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 359 | 0.070 |
Why?
|
| Length of Stay | 2 | 2011 | 1997 | 0.070 |
Why?
|
| Tongue Neoplasms | 1 | 2009 | 253 | 0.070 |
Why?
|
| Ligands | 1 | 2010 | 1007 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 354 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2010 | 1355 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 1072 | 0.070 |
Why?
|
| Heart | 1 | 2013 | 1173 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 318 | 0.070 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 260 | 0.070 |
Why?
|
| Mucous Membrane | 2 | 2018 | 258 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 4642 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 958 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 5056 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 2051 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2010 | 1801 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2010 | 1458 | 0.070 |
Why?
|
| RNA Interference | 1 | 2010 | 1381 | 0.070 |
Why?
|
| Recurrence | 2 | 2011 | 4878 | 0.070 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 10713 | 0.060 |
Why?
|
| Reoperation | 2 | 2019 | 1389 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 1430 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 542 | 0.060 |
Why?
|
| Infant | 3 | 2022 | 13992 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2006 | 179 | 0.060 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2004 | 32 | 0.060 |
Why?
|
| Otitis Media with Effusion | 1 | 2004 | 23 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2011 | 1581 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2013 | 2376 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2011 | 1858 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1044 | 0.060 |
Why?
|
| Facial Paralysis | 1 | 2004 | 57 | 0.060 |
Why?
|
| United States | 4 | 2020 | 15827 | 0.060 |
Why?
|
| Ear, Inner | 1 | 2004 | 64 | 0.060 |
Why?
|
| History, 18th Century | 1 | 2004 | 86 | 0.060 |
Why?
|
| beta Catenin | 1 | 2008 | 687 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 1161 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1956 | 0.060 |
Why?
|
| Peer Review | 1 | 2024 | 82 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4391 | 0.050 |
Why?
|
| Hypertension | 2 | 2010 | 1584 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 2478 | 0.050 |
Why?
|
| Cell Movement | 1 | 2011 | 2468 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1344 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2004 | 219 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2004 | 155 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 906 | 0.050 |
Why?
|
| Oncogenes | 1 | 2006 | 697 | 0.050 |
Why?
|
| Neoplasm Transplantation | 3 | 2012 | 1553 | 0.050 |
Why?
|
| Mutation | 4 | 2020 | 15905 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 457 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2618 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 1580 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 210 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 2050 | 0.050 |
Why?
|
| Patient Selection | 2 | 2020 | 2028 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2023 | 666 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4317 | 0.050 |
Why?
|
| Zambia | 1 | 2020 | 16 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2009 | 4907 | 0.050 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2000 | 144 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 143 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 272 | 0.040 |
Why?
|
| Radiobiology | 1 | 2020 | 56 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1761 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 2882 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2006 | 2134 | 0.040 |
Why?
|
| Neoplasms | 2 | 2024 | 15931 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 5157 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 92 | 0.040 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2019 | 59 | 0.040 |
Why?
|
| Proteogenomics | 1 | 2020 | 110 | 0.040 |
Why?
|
| Device Removal | 1 | 2021 | 339 | 0.040 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2019 | 40 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2006 | 2035 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 3906 | 0.040 |
Why?
|
| Rabbits | 1 | 2000 | 1040 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1586 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2010 | 4104 | 0.040 |
Why?
|
| Transgenes | 1 | 2000 | 568 | 0.040 |
Why?
|
| Genes, Homeobox | 1 | 2019 | 142 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 813 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 172 | 0.040 |
Why?
|
| Maxilla | 1 | 2019 | 86 | 0.040 |
Why?
|
| Radiosurgery | 1 | 2008 | 1389 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 4493 | 0.040 |
Why?
|
| Antifungal Agents | 2 | 2015 | 882 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2020 | 704 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2000 | 551 | 0.040 |
Why?
|
| Survivorship | 1 | 2017 | 116 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 7311 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 796 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 734 | 0.030 |
Why?
|
| Remission Induction | 2 | 2015 | 3658 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 805 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 220 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 12971 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2017 | 230 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 321 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 174 | 0.030 |
Why?
|
| Airway Resistance | 1 | 1995 | 43 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 731 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 517 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 674 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2018 | 417 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 1111 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 536 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 1562 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 907 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 450 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 612 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 2656 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2018 | 402 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 4964 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 930 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 149 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 515 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 911 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 493 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 1124 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 214 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 336 | 0.030 |
Why?
|
| Respiration | 1 | 1995 | 465 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 4202 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 237 | 0.030 |
Why?
|
| Free Tissue Flaps | 1 | 2017 | 374 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2012 | 280 | 0.030 |
Why?
|
| Cell Shape | 1 | 2012 | 126 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 105 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 1581 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1995 | 274 | 0.030 |
Why?
|
| Karyotype | 1 | 2012 | 237 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 781 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 969 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1329 | 0.020 |
Why?
|
| Neurosurgery | 1 | 2012 | 119 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 2356 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 911 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2015 | 488 | 0.020 |
Why?
|
| Cross Infection | 1 | 2015 | 547 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 898 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 721 | 0.020 |
Why?
|
| Metanephrine | 1 | 2010 | 7 | 0.020 |
Why?
|
| Carney Complex | 1 | 2010 | 7 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2395 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 248 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4468 | 0.020 |
Why?
|
| Tonsillectomy | 1 | 2011 | 121 | 0.020 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2010 | 33 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1225 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2010 | 67 | 0.020 |
Why?
|
| Glossectomy | 1 | 2009 | 43 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2392 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2249 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3534 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1307 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 1547 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 333 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A7 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3395 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2008 | 184 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 1993 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 494 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 1002 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1535 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 800 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 1409 | 0.020 |
Why?
|
| Survivors | 1 | 2012 | 1021 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2010 | 571 | 0.020 |
Why?
|
| Colon | 1 | 2009 | 684 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 2674 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4246 | 0.020 |
Why?
|
| Palliative Care | 1 | 2016 | 2175 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 1260 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6344 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 276 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 7050 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2199 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 4837 | 0.010 |
Why?
|
| Smoking | 1 | 2009 | 2549 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3186 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 1995 | 10 | 0.010 |
Why?
|
| Hypercapnia | 1 | 1995 | 28 | 0.010 |
Why?
|
| Plethysmography | 1 | 1995 | 39 | 0.010 |
Why?
|
| Inhalation | 1 | 1995 | 43 | 0.010 |
Why?
|
| Pulmonary Ventilation | 1 | 1995 | 48 | 0.010 |
Why?
|
| Tracheal Diseases | 1 | 1995 | 36 | 0.010 |
Why?
|
| Naloxone | 1 | 1995 | 105 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1995 | 327 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1995 | 418 | 0.010 |
Why?
|
| Eating | 1 | 1995 | 439 | 0.010 |
Why?
|
| Oxygen | 1 | 1995 | 786 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 2140 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1995 | 1824 | 0.010 |
Why?
|
| Rats | 1 | 1995 | 6397 | 0.000 |
Why?
|